Drug manufacturer Lupin on Thursday said the US wellbeing controller has shut the investigation of its assembling office in Pithampur, Madhya Pradesh.

The investigation for the office was led by the US wellbeing controller between February 3 and February 11, 2020, and finished up with two perceptions, the Mumbai-based organization said.

The organization has gotten the foundation investigation report (EIR) from the United States Food and Drug Administration (USFDA) for its Pithampur Unit-1 plant, Lupin said.

The USFDA issues an EIR to an organization when an examination is agreeably shut.

Lupin Managing Director Nilesh Gupta said the organization has gotten the EIR for the plant with Voluntary Action Indicated (VAI) status.

"Consistent improvement of our quality and consistence gauges over the entirety of our assembling destinations is a key center region for the organization and we are focused on working with the USFDA to make and flexibly results of the highest caliber from all our assembling locales," he included.